Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus
Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, double-blinded, randomized, placebo-controlled, phase 2 study to
evaluate the efficacy and safety of sirolimus administered in addition to standard therapy,
in patients with active SLE disease.
Phase:
Phase 2
Details
Lead Sponsor:
Chinese SLE Treatment And Research Group
Collaborators:
Beijing Municipal Science & Technology Commission North China Pharmaceutical Group Corporation